BD LH-0030 - SafeStep Huber Infusion Set, 22G x 1", No Y-Site, 25/PK (Continental US Only)

BD LH-0030 - SafeStep Huber Infusion Set, 22G x 1", No Y-Site, 25/PK (Continental US Only)

The BD LH-0030 SafeStep Huber Infusion Set is a sterile, single-use safety port-access device designed for accessing compatible surgically implanted vascular ports. The set features a 22-gauge non-coring Huber needle with a 1-inch length and is configured without a Y-injection site, providing a streamlined direct fluid pathway for compatible infusion and vascular-access procedures.

The 22-gauge needle provides a smaller access profile suitable for therapies where moderate flow capability is appropriate. Its 1-inch needle length accommodates implanted ports positioned at a moderate depth beneath the skin, helping clinicians select an appropriate access depth based on patient anatomy and port placement.

The SafeStep design incorporates a clear plastic base that improves visibility of the insertion site throughout therapy. Its stable, wingless footprint is designed to support dressing application, patient comfort, and routine access-site assessment.

The set has an approximate priming volume of 0.3 mL and does not include a Y-injection site. This direct configuration may be appropriate for clinical workflows where an integrated secondary medication or fluid-access point is not required.

An integrated safety mechanism activates during needle withdrawal from the implanted port. Audible and visual indications help confirm that the safety device has locked, supporting safer removal, handling, and sharps disposal.

BD LH-0030 is supplied 25 sets per shelfpack and is designed for professional vascular-access applications in hospitals, oncology centers, infusion clinics, and other healthcare environments where implanted ports are routinely accessed.

Key Benefits

• 22-gauge non-coring Huber needle supports access to compatible surgically implanted vascular ports.
• One-inch needle length accommodates ports positioned at a moderate depth beneath the skin.
• Non-coring design helps minimize unnecessary damage to compatible implanted port septa during appropriate access.
• Configuration without a Y-injection site provides a simple, direct fluid pathway.
• Approximate 0.3 mL priming volume supports fluid-management planning.
• Clear plastic base improves visibility of the insertion site during therapy.
• Stable needle base is designed to support patient comfort during dressing and therapy.
• Wingless design facilitates access-site care and dressing application.
• Integrated safety mechanism helps reduce the risk of accidental needlestick exposure during deaccessing.
• Audible click and visual indication help confirm safety lockout.
• Dual-lumen port compatibility supports appropriate multi-lumen implanted port applications.
• Textured handle supports secure clinician grip during access and removal.
• Rotating handle design assists with tubing positioning and dressing management.
• Small footprint may help reduce the amount of dressing material required.
• Manufactured without natural rubber latex in the material formulation.
• DEHP is not part of the product material formulation.
• Ethylene oxide sterilized for sterile clinical use.
• 25-per-shelfpack packaging supports routine clinical inventory management.

Compatibility and Applications

The BD LH-0030 SafeStep Huber Infusion Set is designed for use with compatible surgically implanted subcutaneous vascular-access ports that accept non-coring Huber needles.

Potential clinical applications include chemotherapy administration, antibiotic therapy, hydration, selected parenteral nutrition applications, blood specimen withdrawal, implanted port flushing, maintenance therapy, and other compatible intravenous treatments delivered through an implanted vascular port.

The 22-gauge configuration may be selected when a smaller needle profile and moderate flow requirements are appropriate for the prescribed treatment. Gauge selection should consider medication characteristics, viscosity, desired flow rate, implanted port specifications, infusion equipment, and institutional protocol.

The 1-inch needle length may be appropriate when a 0.75-inch needle does not provide sufficient access depth but a longer 1.5-inch needle is unnecessary. Tissue depth, port position, and patient anatomy should be assessed before selecting the needle length.

Because BD LH-0030 does not include a Y-injection site, the set provides a direct fluid pathway without an integrated secondary access point. This configuration may be useful when the prescribed therapy uses a single primary connection.

The SafeStep platform should not be assumed to be power injectable. For procedures involving high-pressure contrast-media injection, clinicians should use a specifically approved power-injectable port-access device and confirm that every component of the vascular-access system is rated for the intended procedure.

Compatibility should be confirmed with the exact implanted port model, septum design, tissue depth, prescribed therapy, connector system, infusion equipment, dressing materials, and institutional vascular-access policies before use.

Usage Guidelines

The BD LH-0030 should be used only by healthcare professionals trained and authorized to access surgically implanted vascular ports. Current manufacturer instructions, aseptic technique, institutional procedures, and the implanted port manufacturer's directions should be followed throughout the procedure.

• Confirm the patient's identity, prescribed therapy, and implanted port type before beginning the procedure.
• Assess the location and depth of the implanted port before selecting the 1-inch needle length.
• Verify that the 22-gauge configuration is appropriate for the prescribed therapy and required flow characteristics.
• Confirm that a configuration without a Y-injection site meets the planned clinical workflow.
• Inspect the sterile package for punctures, moisture, damage, contamination, or compromised integrity.
• Do not use the device if the package is damaged or the sterile barrier has been compromised.
• Prepare the implanted port site according to institutional skin-antisepsis and sterile-access procedures.
• Prime the fluid pathway completely with an approved solution before accessing the implanted port.
• Remove air from the tubing before connecting the set to the vascular-access system.
• Use the textured handle to maintain controlled positioning during port access.
• Stabilize the implanted port and insert the non-coring needle perpendicular to the port septum using an approved technique.
• Advance the needle carefully until appropriate access to the port reservoir is achieved.
• Verify correct placement according to institutional policy, including aspiration for blood return when clinically appropriate.
• Flush the implanted port according to current manufacturer instructions and facility protocol.
• Rotate and position the tubing as needed to support comfortable dressing placement without excessive pulling or twisting.
• Apply an appropriate sterile dressing while maintaining visibility of the access site through the clear base when possible.
• Monitor the access site for pain, swelling, redness, leakage, displacement, or other abnormalities throughout therapy.
• After therapy, flush and lock the implanted port according to the prescribed protocol.
• Stabilize the implanted port during needle withdrawal.
• Allow the SafeStep safety mechanism to activate according to manufacturer instructions.
• Confirm safety lockout using the audible and visual indicators.
• Dispose of the used device immediately in an approved sharps container.

Stop the procedure and assess the implanted port system if unexpected resistance occurs during flushing, appropriate blood return cannot be obtained when expected, the patient experiences unusual discomfort, or swelling, leakage, displacement, or another abnormality develops at the access site.

Certifications and Safety Standards

The BD LH-0030 SafeStep Huber Infusion Set is designed for professional medical use within established vascular-access, infusion-therapy, infection-prevention, and occupational safety programs.

The product is supplied sterile and is sterilized using ethylene oxide. Sterile package integrity should be verified before use, and the device should not be used when the packaging is open, damaged, wet, contaminated, or otherwise compromised.

The product formulation does not include natural rubber latex or DEHP, supporting procurement requirements in healthcare environments seeking products without these materials.

The integrated safety mechanism is designed to reduce the risk of injury and exposure to bloodborne pathogens during needle withdrawal from an implanted port. Audible and visual indications help clinicians verify that the safety lockout has activated.

The safety feature does not replace appropriate clinician training, personal protective equipment, safe sharps-handling practices, exposure-control procedures, or immediate disposal of the used device in an approved sharps container.

The non-coring Huber needle should be selected according to patient anatomy, implanted port depth, prescribed therapy, required flow characteristics, and current manufacturer instructions.

Healthcare organizations should review current manufacturer labeling and instructions for applicable regulatory status, UDI information, sterilization details, shelf life, storage requirements, warnings, precautions, contraindications, and other product-specific technical requirements.

Comparison with Competitors

Compared with conventional Huber needles without integrated safety technology, the BD SafeStep system incorporates a safety mechanism that activates during needle withdrawal. Audible and visual confirmation of lockout helps support safer handling and sharps disposal.

Compared with Huber infusion sets containing a Y-injection site, BD LH-0030 provides a simpler direct fluid pathway without an integrated secondary access point. This may reduce unnecessary connection complexity when secondary medication or fluid access is not required.

Compared with winged port-access needles, the SafeStep wingless design provides a small, stable footprint intended to facilitate site care, dressing application, and patient comfort.

The clear plastic base differentiates the SafeStep design from more opaque port-access bases by allowing clinicians to maintain better visibility of the insertion site during therapy.

Compared with 19-gauge and 20-gauge Huber needles, the 22-gauge configuration provides a smaller needle profile but generally supports lower flow requirements. Larger-gauge options may be preferred when greater flow capability is clinically necessary.

Compared with 0.75-inch access needles, the 1-inch configuration accommodates ports positioned at a greater tissue depth. Compared with 1.5-inch needles, it may provide a lower access profile when additional length is unnecessary.

Unlike BD PowerLoc Max power-injectable infusion sets, the SafeStep Huber Needle Set should not be selected solely on the assumption that it supports high-pressure contrast injection. A specifically labeled power-injectable access device should be used when power injection is required.

Alternative safety Huber needle sets may vary in gauge, needle length, base design, safety activation method, Y-site availability, priming volume, material formulation, and package quantity. BD LH-0030 combines a 22-gauge, 1-inch non-coring Huber needle with a clear wingless base, integrated safety lockout, no-Y-site configuration, and 0.3 mL priming volume.

Typical User Profile and Application Scenarios

The BD LH-0030 SafeStep Huber Infusion Set is intended for trained healthcare professionals responsible for accessing and managing surgically implanted vascular ports. Typical users include infusion nurses, oncology nurses, vascular-access specialists, physicians, advanced practice clinicians, and other qualified healthcare personnel.

Common use environments include hospitals, oncology centers, outpatient infusion clinics, ambulatory treatment centers, specialty practices, home-infusion programs managed by qualified professionals, and other healthcare settings where implanted vascular ports are routinely accessed.

The product may be selected for patients whose implanted port requires approximately a 1-inch needle length and whose prescribed therapy is compatible with a 22-gauge non-coring access needle.

Typical application scenarios include chemotherapy administration, antibiotic infusion, hydration, selected parenteral nutrition therapies, blood specimen collection, implanted port flushing, and routine port maintenance.

The no-Y-site configuration is particularly relevant for workflows using a direct primary infusion connection that do not require an integrated secondary medication or fluid-access point.

Best Practices for Use and Maintenance

The BD LH-0030 is a sterile, single-use medical device. Best practices focus on proper storage, accurate product selection, sterile preparation, implanted port access, access-site monitoring, safety activation, and disposal.

• Store unopened sets according to current manufacturer-recommended environmental conditions.
• Protect packages from excessive heat, moisture, crushing, punctures, and contamination.
• Rotate inventory according to expiration dates and facility stock-control procedures.
• Verify the BD LH-0030 catalog number before opening the package.
• Confirm the 22-gauge size, 1-inch needle length, and no-Y-site configuration.
• Assess patient tissue depth and implanted port position before selecting the needle length.
• Confirm that the prescribed therapy and required flow characteristics are appropriate for a 22-gauge access device.
• Use strict aseptic technique during preparation, priming, insertion, connection, dressing application, and deaccessing.
• Prime the complete fluid pathway before accessing the implanted vascular port.
• Consider the approximately 0.3 mL priming volume when precise fluid management is clinically important.
• Use the clear base to assist with ongoing visual assessment of the access site.
• Position the tubing carefully to reduce pulling, twisting, and pressure at the implanted port site.
• Maintain an intact dressing according to institutional policy and therapy duration.
• Monitor the implanted port site and tubing connections throughout therapy.
• Do not use the device for power injection unless current manufacturer documentation specifically authorizes the exact product and complete system for the intended procedure.
• Do not bend, cut, modify, repair, or otherwise alter the infusion set.
• Do not reuse or reprocess a device intended for single use.
• Confirm complete safety lockout immediately after needle withdrawal.
• Place the used device directly into an approved sharps container.

Regulatory and Safety Information

The BD LH-0030 SafeStep Huber Infusion Set should be used only by appropriately trained healthcare professionals and only for applications consistent with current manufacturer labeling, implanted port instructions, professional clinical judgment, and institutional policy.

Before use, verify the product identity, 22-gauge size, 1-inch needle length, no-Y-site configuration, sterile package integrity, expiration date, and compatibility with the implanted vascular port. Do not use a product that is expired, damaged, contaminated, or supplied in compromised packaging.

BD identifies LH-0030 with a 0.3 mL priming volume, no Y-injection site, ethylene oxide sterilization, no natural rubber latex in the material formulation, no DEHP in the material formulation, and a three-year shelf life.

The SafeStep Huber Needle Set should not be assumed to be rated for power injection. For high-pressure contrast-media procedures, use a specifically labeled power-injectable port-access set and verify that the implanted port, access needle, tubing, connectors, and all other components are approved for the intended pressure and flow conditions.

Incorrect needle-length selection, incomplete septum access, needle displacement, or improper securement may contribute to infiltration, extravasation, leakage, interrupted therapy, tissue injury, or implanted port complications.

Because BD LH-0030 does not include a Y-injection site, it does not provide an integrated secondary access point within the tubing. Clinical teams should confirm that a direct fluid pathway meets the requirements of the planned therapy before use.

The SafeStep safety mechanism should be activated according to current manufacturer instructions. The used device remains a contaminated sharp after deaccessing and should be discarded immediately in an approved sharps container.

BD lists LH-0030 as 25 units per shelfpack, with 200 units represented at the case GTIN level. Purchasing personnel should verify the current selling unit, availability, storage requirements, shipping eligibility, and applicable return conditions before ordering.

How to Order

Select the BD LH-0030 - SafeStep Huber Infusion Set, 22G x 1", No Y-Site and add it to your cart. Complete checkout with your preferred shipping and payment options. For bulk orders, quotes, or further assistance, contact CIA Medical customer service at (312)275-5850 or use the contact form on this page.